FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090222522> ?p ?o ?g. }

• W2090222522 abstract "Cystic fibrosis (CF) is an inherited condition characterised by the abnormal transport of chloride ions across transporting epithelia. This leads to the production of thick sticky mucus in the lungs, pancreas, liver, intestine and reproductive tract, and an increase in the salt content in sweat. Among other problems, people with CF experience recurrent respiratory infections and have difficulties digesting food. CF affects over 9000 individuals in the UK. CF shortens life expectancy and adversely affects quality of life. In 2010, CF was recorded as the cause of 103 deaths in England and Wales.To evaluate the clinical effectiveness and cost-effectiveness of colistimethate sodium dry powder for inhalation (DPI) (Colobreathe(®), Forest Laboratories) and tobramycin DPI (TOBI Podhaler(®), Novartis Pharmaceuticals) for the treatment of Pseudomonas aeruginosa lung infection in CF.Electronic databases were searched in February and March 2011 [MEDLINE, MEDLINE In-Process & Other Non-Indexed citations, EMBASE, The Cochrane Library databases, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science, Conference Proceedings Citation Index (CPCI) and Bioscience Information Service (BIOSIS) Previews]. Relevant databases were searched for ongoing and unpublished studies, and bibliographies of relevant systematic reviews and the manufacturers' submissions were also hand-searched.A systematic review of the clinical effectiveness and cost-effectiveness of colistimethate sodium DPI and tobramycin DPI for the treatment of chronic P. aeruginosa lung infection in CF was conducted. Existing economic evidence within the literature was reviewed and a de novo health economic model was also developed.Three randomised controlled trials (RCTs) were included in the clinical effectiveness review. Both colistimethate sodium DPI and tobramycin DPI were reported to be non-inferior to nebulised tobramycin for the outcome forced expiratory volume in first second percentage predicted (FEV1%). It was not possible to draw any firm conclusions as to the relative efficacy of colistimethate sodium DPI compared with tobramycin DPI. The economic analysis suggests that colistimethate sodium DPI produces fewer quality-adjusted life-years (QALYs) than nebulised tobramycin. Given the incremental discounted lifetime cost of tobramycin DPI compared with nebulised tobramycin, it highly unlikely that tobramycin DPI has an incremental cost-effectiveness ratio that is better than £30,000 per QALY gained.The uncertainty surrounding the short-term evidence base inevitably results in uncertainty surrounding the long-term clinical effectiveness and cost-effectiveness of colistimethate sodium DPI.Both DPI formulations have been shown to be non-inferior to nebulised tobramycin as measured by FEV1%. The results of these trials should be interpreted with caution owing to the means by which the results were analysed, the length of follow-up, and concerns about the ability of FEV1% to accurately represent changes in lung health. Although the increase in QALYs is expected to be lower with colistimethate sodium DPI than with nebulised tobramycin, a price for this intervention had not been agreed at the time of the assessment. Depending on the price of colistimethate sodium DPI, this results either in a situation whereby colistimethate sodium DPI is dominated by nebulised tobramycin or in one whereby the incremental cost-effectiveness of nebulised tobramycin compared with colistimethate sodium DPI is in the range of £24,000-277,000 per QALY gained. The economic analysis also suggests that, given its price, it is unlikely that tobramycin DPI has a cost-effectiveness ratio of < £30,000 per QALY gained when compared with nebulised tobramycin. A RCT to assess the longer-term (≥ 12 months) efficacy of colistimethate sodium DPI and tobramycin DPI in comparison with nebulised treatments would be beneficial. Such a study should include the direct assessment of HRQoL using a relevant preference-based instrument. Future studies should ensure that the European Medicines Agency guidelines are adhered to. In addition, high-quality research concerning the relationship between forced expiratory volume in first second % (FEV1%) predicted or other measures of lung function and survival/health-related quality of life (HRQoL) would be useful.PROSPERO CRD42011001350.The National Institute for Health Research Health Technology Assessment programme." @default.
• W2090222522 created "2016-06-24" @default.
• W2090222522 creator A5015385670 @default.
• W2090222522 creator A5019483250 @default.
• W2090222522 creator A5041850637 @default.
• W2090222522 creator A5061681421 @default.
• W2090222522 creator A5076501093 @default.
• W2090222522 creator A5091543616 @default.
• W2090222522 date "2013-12-01" @default.
• W2090222522 modified "2023-09-27" @default.
• W2090222522 title "Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model" @default.
• W2090222522 cites W1481098372 @default.
• W2090222522 cites W1481796766 @default.
• W2090222522 cites W1499823044 @default.
• W2090222522 cites W1571205167 @default.
• W2090222522 cites W1573155455 @default.
• W2090222522 cites W1901052440 @default.
• W2090222522 cites W1958034086 @default.
• W2090222522 cites W1958971206 @default.
• W2090222522 cites W1966662184 @default.
• W2090222522 cites W1971558827 @default.
• W2090222522 cites W1974826069 @default.
• W2090222522 cites W1975379303 @default.
• W2090222522 cites W1975806439 @default.
• W2090222522 cites W1983433182 @default.
• W2090222522 cites W1984460749 @default.
• W2090222522 cites W1987865402 @default.
• W2090222522 cites W1987952120 @default.
• W2090222522 cites W1990987230 @default.
• W2090222522 cites W1991875620 @default.
• W2090222522 cites W2011422566 @default.
• W2090222522 cites W2014673448 @default.
• W2090222522 cites W2015944029 @default.
• W2090222522 cites W2017506699 @default.
• W2090222522 cites W2018392439 @default.
• W2090222522 cites W2028566024 @default.
• W2090222522 cites W2029997282 @default.
• W2090222522 cites W2033890227 @default.
• W2090222522 cites W2041239919 @default.
• W2090222522 cites W2042602096 @default.
• W2090222522 cites W2045585264 @default.
• W2090222522 cites W2045873707 @default.
• W2090222522 cites W2046513922 @default.
• W2090222522 cites W2057060986 @default.
• W2090222522 cites W2069621497 @default.
• W2090222522 cites W2069664250 @default.
• W2090222522 cites W2089416236 @default.
• W2090222522 cites W2097575804 @default.
• W2090222522 cites W2097667004 @default.
• W2090222522 cites W2106291554 @default.
• W2090222522 cites W2109939030 @default.
• W2090222522 cites W2111786217 @default.
• W2090222522 cites W2113501330 @default.
• W2090222522 cites W2115505766 @default.
• W2090222522 cites W2116478659 @default.
• W2090222522 cites W2117294447 @default.
• W2090222522 cites W2118312152 @default.
• W2090222522 cites W2120857717 @default.
• W2090222522 cites W2125078269 @default.
• W2090222522 cites W2131539997 @default.
• W2090222522 cites W2136291881 @default.
• W2090222522 cites W2136652636 @default.
• W2090222522 cites W2144711236 @default.
• W2090222522 cites W2149520619 @default.
• W2090222522 cites W2153102800 @default.
• W2090222522 cites W2153807544 @default.
• W2090222522 cites W2161787247 @default.
• W2090222522 cites W2162653125 @default.
• W2090222522 cites W2163772620 @default.
• W2090222522 cites W2164011121 @default.
• W2090222522 cites W2165894675 @default.
• W2090222522 cites W2167789521 @default.
• W2090222522 cites W2171230591 @default.
• W2090222522 cites W2171697262 @default.
• W2090222522 cites W2212853496 @default.
• W2090222522 cites W2337822896 @default.
• W2090222522 cites W2397119706 @default.
• W2090222522 cites W2405513915 @default.
• W2090222522 cites W2444638380 @default.
• W2090222522 cites W2483653404 @default.
• W2090222522 cites W2488072735 @default.
• W2090222522 cites W2586396464 @default.
• W2090222522 cites W2800070106 @default.
• W2090222522 cites W2914209516 @default.
• W2090222522 cites W29861392 @default.
• W2090222522 cites W3135185800 @default.
• W2090222522 cites W3135546954 @default.
• W2090222522 cites W3151002452 @default.
• W2090222522 cites W50779059 @default.
• W2090222522 cites W85469694 @default.
• W2090222522 cites W1227417993 @default.
• W2090222522 doi "https://doi.org/10.3310/hta17560" @default.
• W2090222522 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4781138" @default.
• W2090222522 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24290164" @default.
• W2090222522 hasPublicationYear "2013" @default.
• W2090222522 type Work @default.
• W2090222522 sameAs 2090222522 @default.
• W2090222522 citedByCount "25" @default.
• W2090222522 countsByYear W20902225222013 @default.
• W2090222522 countsByYear W20902225222014 @default.

• next